Known as the bellwether of the health industry, this year's conference was themed "Entering the AI Era: Paradigm Revolution and Pathway Choices for the Health Industry," bringing together nearly 10,000 industry leaders, research experts, and channel elites to jointly explore the industry's digital transformation and high-quality development. The Healthy China · Brand List is built on the 4D-BES quantitative evaluation model, which assesses products across four major dimensions — product value, market value, profit expectations, and user acclaim — through a combination of real operational data from retail pharmacy terminals nationwide, market research, and expert review. It objectively reflects the comprehensive competitiveness of brands in the out-of-hospital market and is a highly recognized honor in the pharmaceutical retail sector.
Since the beginning of this year, Pudilan Xiaoyan Oral Liquid and Xiao'er Chiqiao Qingre Granules (Tonpei) have successively earned multiple prestigious industry honors: in March, both products were listed among the "2025–2026 Best-Selling Products in China's Pharmaceutical Retail Market" at the 2026 Xiding Conference; in April, Pudilan Xiaoyan Oral Liquid was named the "the Most Popular Star Product in Pharmacies" at the Wuzhen Health Conference; and in May, Tonpei was honored with the title of "Thirty-Year Demonstration Variety of TCM Modernization" at the 5th High-Quality TCM Development Conference, while Pudilan Xiaoyan Oral Liquid was approved by the NMPA as a Secondary Protected TCM variety product. This succession of honors represents the consistent recognition of the two products' long-term, stable quality by the industry, retail terminals, professional medical communities, and patients.
This renewed inclusion of Pudilan Xiaoyan Oral Liquid and Xiao'er Chiqiao Qingre Granules (Tonpei) in the Healthy China · Brand List reflects the industry's continued recognition of JumpCan Pharmaceutical's commitment to brand building and its steadfast adherence to quality standards. In the face of industry transformation, JumpCan Pharmaceutical will continue to advance pharmaceutical modernization, consolidate product quality and brand strength, work with channel partners to explore family health needs, and support the Healthy China initiative with quality products — providing accessible, reliable health solutions for the public.